Earnings
Home›Earnings›Analyst Ratings›Bearish bets intensify across Hims & Hers, QXO, and KLA
Bearish bets intensify across Hims & Hers, QXO, and KLA
Hims & Hers faces new FTC and state lawsuits over alleged privacy, billing, and cancellation practices, adding regulatory risk alongside prior debt and deal-driven dilution concerns.
MarketBeat Ratings highlights rising bearish pressure in three stocks, pointing to heavy short interest and valuation concerns across healthcare and semiconductors. The report says Hims & Hers Health and QXO rank among the most heavily shorted names, while KLA has slid nearly 40% since June as AI chip spending concerns weigh on the group.
In Hims & Hers’ case, MarketBeat Ratings points to a new legal overhang: on July 29, the Federal Trade Commission, Utah, and California sued the company over alleged privacy, billing, and cancellation practices. The outlet also notes Hims & Hers missed analyst expectations on both revenue and earnings per share in Q1, with elevated customer acquisition costs raising margin compression risk.
The report adds that in May, Hims & Hers announced a $350 million private offering of convertible senior notes due June 1, 2032, which stoked dilution fears even though it included capped-call transactions aimed at reducing potential dilution. MarketBeat Ratings says much of the offering is earmarked for the Eucalyptus acquisition, while also supporting the company’s longer-term international expansion plan.
For QXO and KLA, the report ties the bearish shift to different mechanisms. MarketBeat Ratings links QXO to the short-selling side of the crowded trade, while it attributes KLA’s downturn to a valuation-driven sell-off amid concerns about chipmakers’ capital spending and the durability of AI demand.